ATXS Latest Press Releases

-- December 20, 2025 --

Halper Sadeh LLC Encourages ATXS, GDOT, UBFO Shareholders to Contact the Firm to Discuss Their Rights Globe Newswire 11:31 AM

-- December 19, 2025 --

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ATXS, MBCN, FMNB, and SEMR PRNewswire 5:00 PM

-- December 1, 2025 --

Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights PRNewswire 6:59 PM

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--TCBX, RNA, ATXS, and FSUN PRNewswire 3:20 PM

-- November 22, 2025 --

Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their Rights Globe Newswire 5:41 AM

-- November 21, 2025 --

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-SPNS, PCH, ATXS, and RYN PRNewswire 5:30 PM

-- November 12, 2025 --

Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights PRNewswire 1:55 PM

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Business Wire 8:00 AM

-- November 6, 2025 --

Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart Business Wire 8:00 AM

-- October 31, 2025 --

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting Business Wire 8:00 AM

-- October 27, 2025 --

HALPER SADEH LLC ENCOURAGES PLYM, HOLX, ATXS, PCH SHAREHOLDERS to Contact the Firm to Discuss Their Rights Globe Newswire 4:51 PM

-- October 21, 2025 --

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HOLX, TRUE, PCH, ATXS on Behalf of Shareholders PRNewswire 1:50 PM

-- October 18, 2025 --

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates RYN, PCH, ATXS on Behalf of Shareholders Globe Newswire 11:41 AM

-- October 17, 2025 --

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS Business Wire 3:20 PM

-- October 16, 2025 --

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates TRUE, AKRO, PCH, ATXS on Behalf of Shareholders Globe Newswire 9:11 PM

-- October 15, 2025 --

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS and RYN on Behalf of Shareholders Globe Newswire 7:30 AM

-- October 14, 2025 --

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS) PRNewswire 9:05 PM

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates ATXS, PCH, RYN on Behalf of Shareholders PRNewswire 12:01 PM

Shareholder Alert: The Ademi Firm investigates whether Astria Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders PRNewswire 11:25 AM

ATXS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Astria Therapeutics, Inc. Is Fair to Shareholders Business Wire 8:29 AM

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile Globe Newswire 7:00 AM

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile Business Wire 7:00 AM

-- October 9, 2025 --

Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting Business Wire 8:00 AM

-- October 8, 2025 --

Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema Business Wire 8:00 AM

-- October 3, 2025 --

Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA Business Wire 8:00 AM

-- October 2, 2025 --

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:10 PM

Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial Business Wire 8:00 AM

-- September 17, 2025 --

Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology Business Wire 8:00 AM

-- September 3, 2025 --

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:10 PM

Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025 Business Wire 8:00 AM

-- August 27, 2025 --

Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference Business Wire 8:00 AM

-- August 12, 2025 --

Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Business Wire 4:10 PM

-- August 6, 2025 --

Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan Business Wire 8:00 AM

-- August 4, 2025 --

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:10 PM